GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Financial Strength

Agenus (Agenus) Financial Strength : 3 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Agenus Financial Strength?

Agenus has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Agenus Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Agenus did not have earnings to cover the interest expense. Agenus's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.23. As of today, Agenus's Altman Z-Score is -10.22.


Competitive Comparison of Agenus's Financial Strength

For the Biotechnology subindustry, Agenus's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Financial Strength distribution charts can be found below:

* The bar in red indicates where Agenus's Financial Strength falls into.



Agenus Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Agenus's Interest Expense for the months ended in Dec. 2023 was $-44.2 Mil. Its Operating Income for the months ended in Dec. 2023 was $-4.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $75.3 Mil.

Agenus's Interest Coverage for the quarter that ended in Dec. 2023 is

Agenus did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Agenus's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.733 + 75.279) / 335.204
=0.23

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Agenus has a Z-score of -10.22, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -10.22 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agenus  (NAS:AGEN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Agenus has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Agenus Financial Strength Related Terms

Thank you for viewing the detailed overview of Agenus's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010